News Breaks |
|
|
| September 21, 2012 |
| 12:00 EDT |  | HALO | Halozyme rises 29.6%
Halozyme is up 29.6%, or $1.90, to $8.31 |
|
|
News For HALO From The Last 14 Days Check below for free stories on HALO the last two weeks. |
|
|
| May 23, 2013 |
| 11:26 EDT |  | HALO | High option volume stocks: HALO DXJ DVY XIDE DRIV
 Subscribe for More Information |
|
| 08:03 EDT |  | HALO | Halozyme names David Ramsay CFO
Subscribe for More Information |
|
| May 21, 2013 |
| 09:09 EDT | | HALO | Baxter granted authorization by European Commission for use of HyQvia
Baxter International (BAX) and Halozyme Therapeutics (HALO) announced that the European Commission has granted Baxter marketing authorization in all European Union Member States for the use of HyQvia as replacement therapy for adult patients with primary and secondary immunodeficiencies. Baxter will introduce HyQvia in select countries during 2013 and plans to expand the launch to other EU countries in 2014. |
|
| May 16, 2013 |
| 08:42 EDT |  | HALO | Halozyme data favorable, says JMP Securities
JMP Securities was highly encouraged by data from a Phase I trial of Halozyme's PEGPH20 in pancreatic cancer, as the drug generated response rates that were significantly higher than competing drugs, according to the firm. JMP Securities raised its target on Halozyme to $12 from $10 and reiterates an Outperform rating on the shares. |
|
| May 15, 2013 |
| 18:07 EDT | | HALO | Halozyme to present new PEGPH20 phase 1b trial data
Halozyme Therapeutics announced that clinical data from a phase 1b trial of PEGPH20, an investigational new biologic, in combination with gemcitabine for treatment of patients with stage IV metastatic pancreatic cancer will be presented at the 2013 American Society of Clinical Oncology annual meeting. In this phase 1b study, 28 stage IV pancreatic ductal adenocarcinoma patients were treated with PEGPH20 in combination with gemcitabine. The overall response rate was 42%as assessed by independent review at therapeutic dose levels of PEGPH20. Treatment was generally well tolerated and the adverse event profile was consistent with those seen in previous studies of PEGPH20 as a single agent and as previously reported for gemcitabine alone. There was no evidence of new observed toxicity. Based on the magnitude of response and safety observed in the Phase 1b study, Halozyme announced in April the initiation of a Phase 2 multicenter, randomized clinical trial evaluating PEGPH20 as a first-line therapy for patients with stage IV metastatic pancreatic cancer. |
|
| 10:13 EDT |  | HALO | On The Fly: Analyst Initiation Summary
Subscribe for More Information |
|
| May 14, 2013 |
| 16:08 EDT | | HALO | Halozyme initiated with an Overweight at Piper Jaffray
Subscribe for More Information |
|
|
|
|
|
